Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Novo Nordisk and Oxford University to Further Enhance Diabetes Research

Published: Tuesday, November 05, 2013
Last Updated: Tuesday, November 05, 2013
Bookmark and Share
Partnership will establish a number of postdoctoral fellowship opportunities hosted by Oxford University and funded by Novo Nordisk.

Oxford University and Novo Nordisk announce the establishment of an international fellowship programme that aims to support the career and scientific development of young, exceptional research talent within diabetes. 

“We are honoured to establish the International PostDoctoral Fellowship Programme with Oxford University, which has such valuable expertise in the study and treatment of diabetes. By combining our company’s discovery and clinical development strengths with the research expertise and academic tradition of Oxford University, we can support the development of a new generation of exceptional diabetes researchers to eventually drive innovation further and improve the lives of the patients,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk.

As part of the agreement, a total of 12 young leading researchers will be offered a 3-year grant to support their research within the fields of diabetes, metabolism and endocrinology. The goal of the new programme is to support the development of a new generation of research leaders while further developing scientific excellence within diabetes. 

“This new programme will support the best young researchers doing novel work in the understanding of diabetes and its treatment. It is these early career researchers that will produce the new ideas, discoveries and advances that will improve diabetes treatment and care in the future. We’re delighted to partner with Novo Nordisk to provide this level of funding and support which will be important in enabling both their research and their career development,” said Professor Hugh Watkins of the Radcliffe Department of Medicine at Oxford University.

A joint steering committee with members from both Oxford University and Novo Nordisk will oversee the programme and assess research proposals from scientists at both organisations. 

The first four fellows in the programme will start in the autumn of 2014.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Introducing Novo Nordisk Pharmatech A/S
Novo Nordisk Pharmatech A/S is now a fully-fledged member of the Novo Nordisk family.
Friday, October 09, 2015
Novo Nordisk Buys New Hampshire Production Plant
Novo Nordisk announced the acquisition of a manufacturing facility in West Lebanon, New Hampshire, USA, from Olympus Biotech.
Thursday, August 28, 2014
Novo Nordisk Expects to Hire 6,000 Employees by 2022
Up to 2022, Novo Nordisk expects to hire 6,000 new employees in Denmark, half of whom will work within research and development.
Wednesday, June 11, 2014
Novo Nordisk Invests $100M in New Danish Purification Pilot Plant
Company increasing its drug development capacity by investing 550 million Danish kroner in a new research and development facility in Bagsværd, Denmark.
Monday, March 17, 2014
Novo Nordisk Receive Positive Opinions from the European Regulatory Authorities
The Committee for Medicinal Products for Human Use adopted positive opinions, recommending marketing authorisations, for Tresiba® and Ryzodeg® for the treatment of diabetes mellitus in adults.
Tuesday, October 23, 2012
Top researcher takes over as Director of the Protein Center
Jiri Lukas will join The Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen on 1 April.
Thursday, March 01, 2012
Novo Nordisk Establishes Type 1 Diabetes R&D Center in Seattle
The new center will combine Novo Nordisk's history in diabetes treatment with the company's growing expertise in immunotherapy.
Wednesday, January 25, 2012
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos